Reaction
Secondary Progressive Multiple Sclerosis reporting signals
As of the last recalculation, Secondary Progressive Multiple Sclerosis appears in 1,871 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is SIPONIMOD (PRR 89.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Siponimod | 69 | 89.3 | 90.0 |
| Fingolimod Hcl | 291 | 44.1 | 44.3 |
| Natalizumab | 502 | 41.6 | 41.7 |
| Glatiramer Acetate | 196 | 40.6 | 40.8 |
| Dalfampridine | 222 | 38.9 | 39.0 |
| Interferon Beta-1A | 470 | 35.8 | 35.9 |
| Teriflunomide | 91 | 23.5 | 23.5 |
| Dimethyl Fumarate | 228 | 23.3 | 23.4 |
| Interferon Beta-1B | 39 | 23.1 | 23.1 |
| Baclofen | 163 | 23.0 | 23.0 |
| Diroximel Fumarate | 22 | 20.8 | 20.8 |
| Peginterferon Beta-1A | 21 | 18.0 | 18.0 |
| Modafinil | 48 | 16.9 | 17.0 |
| Tizanidine Hydrochloride | 25 | 15.6 | 15.6 |
| Ocrelizumab | 83 | 15.5 | 15.6 |
| Tolterodine Tartrate | 12 | 15.0 | 15.0 |
| Ofatumumab | 42 | 14.4 | 14.4 |
| Oxybutynin Chloride | 11 | 14.0 | 14.1 |
| Rizatriptan Benzoate | 10 | 11.0 | 11.0 |
| Oxybutynin | 27 | 10.4 | 10.4 |
| Amantadine | 13 | 9.4 | 9.4 |
| Fesoterodine Fumarate | 9 | 9.3 | 9.3 |
| Tizanidine | 15 | 7.0 | 7.0 |
| Armodafinil | 12 | 6.4 | 6.4 |
| Mirabegron | 17 | 4.9 | 4.9 |
| Ozanimod Hydrochloride | 3 | 4.0 | 4.0 |
| Pseudoephedrine Hcl | 3 | 3.0 | 3.0 |